Investors Tell Chancery CytoDyn Board Ignored Drug Scheme

Stockholders of CytoDyn Inc. have filed a consolidated derivative complaint in the Delaware Chancery Court, accusing the company's leadership of wrongfully refusing to investigate and sue its former CEO and others...

Already a subscriber? Click here to view full article